Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 4Phase 1 3Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 38Specimen Handling 37Magnetic Resonance Spectroscopy 26Biopsy 26Cyclophosphamide 25Carboplatin 25fludarabine 21Nivolumab 20Gemcitabine 18Dexamethasone 18Paclitaxel 15Rituximab 13Bevacizumab 13Pemetrexed 12Docetaxel 12atezolizumab 11Cisplatin 11Lenalidomide 10Ipilimumab 10Fulvestrant 10venetoclax 9Prednisone 9Oxaliplatin 9olaparib 8fludarabine phosphate 8belantamab mafodotin 8Temozolomide 8Injections 8Fluorouracil 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × niraparib × 30 days × Clear all
NCT04037254 2026-05-20

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

NRG Oncology

Phase 1/2 Completed
22 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡